INVX vs REGN · P/E 8.0, rev $660.8M vs P/E 14, rev $14.34B
Innovex International, Inc (INVX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Innovex International, Inc (INVX) is a oil & gas equipment & services company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported INVX revenue for 2024-12-31 was $660.8M. Net income was $140.3M. Revenue was up 55.8% from 2023-12-31 to 2024-12-31. INVX currently screens at market cap $1.10B and trailing P/E 8.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
INVX currently screens at market cap $1.10B and trailing P/E 8.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the INVX and REGN stock pages for the full models.
Not investment advice.